15–20% of breast cancers overexpress HER2 and data from neoadjuvant trials have shown that these tumours may be relatively resistant to tamoxifen but remain sensitive to AIs (Ellis et al, 2001). This evidence concerns the gene ERBB2 and breast carcinoma.